FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313305832> ?p ?o ?g. }

• W4313305832 endingPage "2445" @default.
• W4313305832 startingPage "2436" @default.
• W4313305832 abstract "Abstract Background: Cancer immunotherapy has emerged as a promising strategy against triple-negative breast cancer (TNBC). One of the immunosuppressive pathways involves programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), but many patients derived little benefit from PD-1/PD-L1 checkpoint blockades treatment. Prior research has shown that MYC , a master transcription amplifier highly expressed in TNBC cells, can regulate the tumor immune microenvironment and constrain the efficacy of immunotherapy. This study aims to investigate the regulatory relationship between MYC and PD-L1, and whether a cyclin-dependent kinase (CDK) inhibitor that inhibits MYC expression in combination with anti-PD-L1 antibodies can enhance the response to immunotherapy. Methods: Public databases and TNBC tissue microarrays were used to study the correlation between MYC and PD-L1. The expression of MYC and PD-L1 in TNBCs was examined by quantitative real-time polymerase chain reaction and Western blotting. A patient-derived tumor xenograft (PDTX) model was used to evaluate the influence of a CDK7 inhibitor THZ1 on PD-L1 expression. Cell proliferation and migration were detected by 5-ethynyl-2′-deoxyuridine (EdU) cell proliferation and cell migration assays. Tumor xenograft models were established for in vivo verification. Results: A high MYC expression level was associated with a poor prognosis and could alter the proportion of tumor-infiltrating immune cells (TIICs). The positive correlation between MYC and PD-L1 was confirmed by immunostaining samples from 165 TNBC patients. Suppression of MYC in TNBC caused a reduction in the levels of both PD-L1 messenger RNA and protein. In addition, antitumor immune response was enhanced in the TNBC cancer xenograft mouse model with suppression of MYC by CDK7 inhibitor THZ1. Conclusions: The combined therapy of CDK7 inhibitor THZ1 and anti-PD-L1 antibody appeared to have a synergistic effect, which might offer new insight for enhancing immunotherapy in TNBC." @default.
• W4313305832 created "2023-01-06" @default.
• W4313305832 creator A5000237640 @default.
• W4313305832 creator A5011320158 @default.
• W4313305832 creator A5012949593 @default.
• W4313305832 creator A5023642600 @default.
• W4313305832 creator A5027094984 @default.
• W4313305832 creator A5028293439 @default.
• W4313305832 creator A5035198764 @default.
• W4313305832 creator A5057733821 @default.
• W4313305832 creator A5068883518 @default.
• W4313305832 creator A5072897591 @default.
• W4313305832 creator A5075493474 @default.
• W4313305832 creator A5076707102 @default.
• W4313305832 date "2022-10-20" @default.
• W4313305832 modified "2023-09-30" @default.
• W4313305832 title "Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer" @default.
• W4313305832 cites W1985987855 @default.
• W4313305832 cites W2004071564 @default.
• W4313305832 cites W2021536610 @default.
• W4313305832 cites W2042699075 @default.
• W4313305832 cites W2072684537 @default.
• W4313305832 cites W2124427232 @default.
• W4313305832 cites W2149765709 @default.
• W4313305832 cites W2150770343 @default.
• W4313305832 cites W2153056550 @default.
• W4313305832 cites W2170846478 @default.
• W4313305832 cites W2295526061 @default.
• W4313305832 cites W2297638727 @default.
• W4313305832 cites W2345415641 @default.
• W4313305832 cites W2560836545 @default.
• W4313305832 cites W2590136228 @default.
• W4313305832 cites W2607129810 @default.
• W4313305832 cites W2613186675 @default.
• W4313305832 cites W2792303880 @default.
• W4313305832 cites W2792645148 @default.
• W4313305832 cites W2795798534 @default.
• W4313305832 cites W2878292361 @default.
• W4313305832 cites W2897422388 @default.
• W4313305832 cites W2919645054 @default.
• W4313305832 cites W2944651921 @default.
• W4313305832 cites W2978006334 @default.
• W4313305832 cites W2987133675 @default.
• W4313305832 cites W2997194092 @default.
• W4313305832 cites W3005529941 @default.
• W4313305832 cites W3009771829 @default.
• W4313305832 cites W3012427153 @default.
• W4313305832 cites W3025384039 @default.
• W4313305832 cites W3094130593 @default.
• W4313305832 cites W3134553072 @default.
• W4313305832 cites W3191177342 @default.
• W4313305832 cites W3202446623 @default.
• W4313305832 cites W3203140854 @default.
• W4313305832 cites W3206299114 @default.
• W4313305832 cites W4200015702 @default.
• W4313305832 cites W4200530094 @default.
• W4313305832 cites W4225845169 @default.
• W4313305832 cites W4225992473 @default.
• W4313305832 cites W4226167851 @default.
• W4313305832 doi "https://doi.org/10.1097/cm9.0000000000002329" @default.
• W4313305832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36583862" @default.
• W4313305832 hasPublicationYear "2022" @default.
• W4313305832 type Work @default.
• W4313305832 citedByCount "3" @default.
• W4313305832 countsByYear W43133058322023 @default.
• W4313305832 crossrefType "journal-article" @default.
• W4313305832 hasAuthorship W4313305832A5000237640 @default.
• W4313305832 hasAuthorship W4313305832A5011320158 @default.
• W4313305832 hasAuthorship W4313305832A5012949593 @default.
• W4313305832 hasAuthorship W4313305832A5023642600 @default.
• W4313305832 hasAuthorship W4313305832A5027094984 @default.
• W4313305832 hasAuthorship W4313305832A5028293439 @default.
• W4313305832 hasAuthorship W4313305832A5035198764 @default.
• W4313305832 hasAuthorship W4313305832A5057733821 @default.
• W4313305832 hasAuthorship W4313305832A5068883518 @default.
• W4313305832 hasAuthorship W4313305832A5072897591 @default.
• W4313305832 hasAuthorship W4313305832A5075493474 @default.
• W4313305832 hasAuthorship W4313305832A5076707102 @default.
• W4313305832 hasBestOaLocation W43133058321 @default.
• W4313305832 hasConcept C121608353 @default.
• W4313305832 hasConcept C126322002 @default.
• W4313305832 hasConcept C190283241 @default.
• W4313305832 hasConcept C193270364 @default.
• W4313305832 hasConcept C203014093 @default.
• W4313305832 hasConcept C2776090121 @default.
• W4313305832 hasConcept C2776107976 @default.
• W4313305832 hasConcept C2777701055 @default.
• W4313305832 hasConcept C2780110267 @default.
• W4313305832 hasConcept C3020616263 @default.
• W4313305832 hasConcept C31573885 @default.
• W4313305832 hasConcept C502942594 @default.
• W4313305832 hasConcept C530470458 @default.
• W4313305832 hasConcept C55493867 @default.
• W4313305832 hasConcept C71924100 @default.
• W4313305832 hasConcept C86803240 @default.
• W4313305832 hasConcept C8891405 @default.
• W4313305832 hasConceptScore W4313305832C121608353 @default.
• W4313305832 hasConceptScore W4313305832C126322002 @default.

• next